Scarica l'app Stockscreener
45.88
0.59%
-0.27
Dopo l'orario di chiusura:
45.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$46.15
Aprire:
$45.95
Volume 24 ore:
1.01M
Relative Volume:
1.46
Capitalizzazione di mercato:
$3.33B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-7.7239
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
-1.23%
1M Prestazione:
+1.64%
6M Prestazione:
+35.54%
1 anno Prestazione:
+75.85%
Intervallo 1D:
$45.52
$47.53
Intervallo di 1 settimana:
$44.82
$47.53
Portata 52W:
$23.58
$54.16
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
45.88 | 3.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Cowen raises PTC Therapeutics stock price target to $50 - MSN
(PTCT) Technical Data - Stock Traders Daily
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $55.00 Consensus PT from Analysts - Defense World
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Analysts Issue Forecasts for PTCT FY2025 Earnings - Defense World
What is Leerink Partnrs’ Forecast for PTCT FY2024 Earnings? - Defense World
What is Leerink Partnrs' Estimate for PTCT FY2024 Earnings? - MarketBeat
PTC Therapeutics Stock Soars on Novartis Licensing Agreement - MSN
Assenagon Asset Management S.A. Sells 52,794 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
FY2024 EPS Estimates for PTCT Lifted by Cantor Fitzgerald - Defense World
William Blair Lifts Earnings Estimates for PTC Therapeutics - Defense World
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
William Blair Boosts Earnings Estimates for PTC Therapeutics - MarketBeat
PTC Therapeutics' SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com Australia
Cantor Fitzgerald Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics sees several potential catalysts in 2025 - MSN
Orsini the Exclusive Specialty Pharmacy Provider for Gene Therapy KEBILIDI™ (eladocagene exuparvovec-tneq) - Yahoo Finance
Muscular Dystrophy Treatment Market Next Big Thing Forecast By 2031 | Santhera Pharmaceuticals, PTC Therapeutics - openPR
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
PTC Therapeutics Surpasses Revenue Guidance for 2024 - TipRanks
PTC Therapeutics reports $814 million in 2024 revenue, surpassing goals - Investing.com
PTC Therapeutics reports $814 million in 2024 revenue, surpassing goals By Investing.com - Investing.com South Africa
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference - Longview News-Journal
Ptc Therapeutics' chief accounting officer sells $132,492 in stock - Investing.com India
Ptc Therapeutics' chief accounting officer sells $132,492 in stock By Investing.com - Investing.com South Africa
PTC Therapeutics CEO Eric Pauwels sells $167,550 in stock By Investing.com - Investing.com South Africa
Ptc Therapeutics exec VP sells shares worth $158,870 By Investing.com - Investing.com Australia
Ptc Therapeutics CEO Matthew Klein sells $204,007 in stock - Investing.com India
Ptc Therapeutics CEO Matthew Klein sells $204,007 in stock By Investing.com - Investing.com Australia
Ptc Therapeutics exec VP sells shares worth $158,870 - Investing.com India
Ptc therapeutics' EVP sells $90,036 in stock By Investing.com - Investing.com Australia
PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden Sells 810 Shares - MarketBeat
Insider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Sells 1,543 Shares of Stock - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,291 Shares - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 1,265 Shares - MarketBeat
Ptc therapeutics’ EVP sells $90,036 in stock By Investing.com - Investing.com Nigeria
PTC Therapeutics CEO Eric Pauwels sells $167,550 in stock - Investing.com
Ptc Therapeutics executive Neil Almstead sells shares worth $133,674 - Investing.com
Ptc therapeutics' EVP sells $90,036 in stock - Investing.com
JPMorgan Chase & Co. Cuts Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Denali Suffers Another ALS Fail With Phase II/III Flop - BioSpace
Have Insiders Sold PTC Therapeutics Shares Recently? - Simply Wall St
Where are the Opportunities in (PTCT) - Stock Traders Daily
Ptc Therapeutics CEO Matthew Klein sells $373,879 in stock By Investing.com - Investing.com Australia
Ptc Therapeutics CEO Matthew Klein sells $373,879 in stock - Investing.com India
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew B. Klein Sells 8,279 Shares - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):